|
1.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics. CA Cancer J Clin. 60:277–300. 2010.
|
|
3.
|
Reungwetwattana T, Weroha SJ and Molina
JR: Oncogenic pathways, molecularly targeted therapies and
highlighted clinical trials in non-small-cell lung cancer (nsclc).
Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Fossella F, Pereira JR, von Pawel J,
Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna
A, Fidias P, Millward M and Belani CP: Randomized, multinational,
phase III study of docetaxel plus platinum combinations versus
vinorelbine plus cisplatin for advanced non-small-cell lung cancer:
the TAX 326 study group. J Clin Oncol. 21:3016–3024. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Kelly K, Crowley J, Bunn PA Jr, Presant
CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR,
Moore DF, Israel VK, Livingston RB and Gandara DR: Randomized phase
III trial of paclitaxel plus carboplatin versus vinorelbine plus
cisplatin in the treatment of patients with advanced non-small-cell
lung cancer: a Southwest Oncology Group trial. J Clin Oncol.
19:3210–3218. 2001.PubMed/NCBI
|
|
6.
|
Kelly K, Crowley J, Bunn PA Jr, Presant
CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR,
Moore DF, Israel VK, Livingston RB and Gandara DR: Phase III
randomized trial comparing three platinum-based doublets in
advanced non-small-cell lung cancer. J Clin Oncol. 20:4285–4291.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology Group: Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar
|
|
8.
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Lydia WSF and Marcia CH: Metabolic
regulation by SIRT3: implications for tumorigenesis. Trends Mol
Med. 18:516–523. 2012. View Article : Google Scholar
|
|
10.
|
Finley LW, Carracedo A, Lee J, Souza A,
Egia A, Zhang J, Teruya-Feldstein J, Moreira PI, Cardoso SM, Clish
CB, Pandolfi PP and Haigis MC: SIRT3 opposes reprogramming of
cancer cell metabolism through HIF1α destabilization. Cancer Cell.
19:416–428. 2011.PubMed/NCBI
|
|
11.
|
Sundaresan NR, Samant SA, Pillai VB,
Rajamohan SB and Gupta MP: SIRT3 is a stress-responsive deacetylase
in cardiomyocytes that protects cells from stress-mediated cell
death by deacetylation of Ku70. Mol Cell Biol. 28:6384–6401. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Li H, Bergeron L, Cryns V, Pasternack MS,
Zhu H, Shi L, Greenberg A and Yuan J: Activation of caspase-2 in
apoptosis. J Biol Chem. 272:21010–21017. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Hirota T, Kunitoku N, Sasayama T, Marumoto
T, Zhang D, Nitta M, Hatakeyama K and Saya H: Aurora-A and an
interacting activator, the LIM protein Ajuba, are required for
mitotic commitment in human cells. Cell. 114:585–598. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Jack F, Ming J and Jo M: Cancer-specific
functions of SIRT1 enable human epithelial cancer cell growth and
survival. Cancer Res. 65:10457–10463. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Hamamoto R, Furukawa Y, Morita M, Iimura
Y, Silva FP, Li M, Yagyu R and Nakamura Y: SMYD3 encodes a histone
methyltransferase involved in the proliferation of cancer cells.
Nat Cell Biol. 6:731–740. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Sood R, Bonner TI, Makalowska I, Stephan
DA, Robbins CM, Connors TD, Morgenbesser SD, Su K, Faruque MU,
Pinkett H, Graham C, Baxevanis AD, Klinger KW, Landes GM, Trent JM
and Carpten JD: Cloning and characterization of 13 novel
transcripts and the human RGS8 gene from the 1q25 region
encompassing the hereditary prostate cancer (HPC1) locus. Genomics.
73:211–222. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Kusumanchi P, Zhang Y, Jani MB, Jayaram
NH, Khan RA, Tang Y, Antony AC and Jayaram HN: Nicotinamide
mononucleotide adenylyltransferase 2 overexpression enhances
colorectal cancer cell-kill by Tiazofurin. Cancer Gene Ther.
20:403–412. 2013. View Article : Google Scholar
|
|
18.
|
Berger F, Lau C, Dahlmann M and Ziegler M:
Subcellular compartmentation and differential catalytic properties
of the three human nicotinamide mononucleotide adenylyltransferase
isoforms. J Biol Chem. 280:36334–36341. 2005. View Article : Google Scholar
|
|
19.
|
Mayer PR, Huang N, Dewey CM, Dries DR,
Zhang H and Yu G: Expression, localization and biochemical
characterization of nicotinamide mononucleotide adenylyltransferase
2. J Biol Chem. 285:40387–40396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Raffaelli N, Lorenzi T, Emanuelli M, Amici
A, Ruggieri S and Magni G: Nicotinamide-mononucleotide
adenylyltransferase from Sulfolobus solfataricus. Methods Enzymol.
331:281–292. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Raffaelli N, Sorci L, Amici A, Emanuelli
M, Mazzola F and Magni G: Identification of a novel human
nicotinamide mono-nucleotide adenylyltransferase. Biochem Biophys
Res Commun. 297:835–840. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Yan T, Feng Y, Zheng J, Ge X, Zhang Y, Wu
D, Zhao J and Zhai Q: Nmnat2 delays axon degeneration in superior
cervical ganglia dependent on its NAD synthesis activity. Neurochem
Int. 56:101–106. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Gilley J and Coleman MP: Endogenous Nmnat2
is an essential survival factor for maintenance of healthy axons.
PLoS Biol. 8:e10003002010. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Lau C, Dölle C, Gossmann TI, Agledal L,
Niere M and Ziegler M: Isoform-specific targeting and interaction
domains in human nicotinamide mononucleotide adenylyltransferases.
J Biol Chem. 285:18868–18876. 2010.PubMed/NCBI
|
|
25.
|
Rose G, Dato S, Altomare K, Bellizzi D,
Garasto S, Greco V, Passarino G, Feraco E, Mari V, Barbi C, BonaFe
M, Franceschi C, Tan Q, Boiko S, Yashin AI and De Benedictis G:
Variability of the SIRT3 gene, human silent information regulator
Sir2 homologue and survivorship in the elderly. Exp Gerontol.
38:1065–1070. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Shi T, Wang F, Stieren E and Tong Q:
SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial
function and thermogenesis in brown adipocytes. J Biol Chem.
280:13560–13567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Ahn BH, Kim HS, Song S, Lee IH, Liu J,
Vassilopoulos A, Deng CX and Finkel T: A role for the mitochondrial
deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad
Sci USA. 105:14447–14452. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Hallows WC, Lee S and Denu JM: Sirtuins
deacetylate and activate mammalian acetyl-CoA synthetases. Proc
Natl Acad Sci USA. 103:10230–10235. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Pillai VB, Sundaresan NR, Kim G, Gupta M,
Rajamohan SB, Pillai JB, Samant S, Ravindra PV, Isbatan A and Gupta
MP: Exogenous NAD blocks cardiac hypertrophic response via
activation of the SIRT3-LKB1-AMP-activated kinase pathway. J Biol
Chem. 285:3133–3144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Sundaresan NR, Gupta M, Kim G, Rajamohan
SB, Isbatan A and Gupta MP: Sirt3 blocks the cardiac hypertrophic
response by augmenting Foxo3a-dependent antioxidant defense
mechanisms in mice. J Clin Invest. 119:2758–2771. 2009.PubMed/NCBI
|
|
31.
|
Sokoloff L: Relationships among local
functional activity, energy metabolism and blood flow in the
central nervous system. Fed Proc. 40:2311–2316. 1981.PubMed/NCBI
|
|
32.
|
Mattson MP and Liu D: Energetics and
oxidative stress in synaptic plasticity and neurodegenerative
disorders. Neuromolecular Med. 2:215–231. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Du L, Zhang X, Han YY, Burke NA, Kochanek
PM, Watkins SC, Graham SH, Carcillo JA, Szabó C and Clark RS:
Intramitochondrial Poly (ADP-ribosylation) contributes to
NAD+ depletion and cell death induced by oxidative
stress. J Biol Chem. 278:18426–18433. 2003.PubMed/NCBI
|
|
34.
|
Zeng J, Yang GY, Ying W, Kelly M, Hirai K,
James TL, Swanson RA and Litt L: Pyruvate improves recovery after
PARP-1-associated energy failure induced by oxidative stress in
neonatal rat cerebrocortical slices. J Cereb Blood Flow Metab.
27:304–315. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Araki T, Sasaki Y and Milbrandt J:
Increased nuclear NAD biosynthesis and SIRT1 activation prevent
axonal degeneration. Science. 305:1010–1013. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Wang J, Zhai Q, Chen Y, Lin E, Gu W,
McBurney MW and He Z: A local mechanism mediates NAD-dependent
protection of axon degeneration. J Cell Biol. 170:349–355. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Kaundal RK, Shah KK and Sharma SS:
Neuroprotective effects of NU1025, a PARP inhibitor in cerebral
ischemia are mediated through reduction in NAD depletion and DNA
fragmentation. Life Sci. 79:2293–2302. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Ying W, Wei G, Wang D, Wang Q, Tang X, Shi
J, Zhang P and Lu H: Intranasal administration with NAD+
profoundly decreases brain injury in a rat model of transient focal
ischemia. Front Biosci. 12:2728–2734. 2007.PubMed/NCBI
|
|
39.
|
Liu D, Pitta M and Mattson MP: Preventing
NAD (+) depletion protects neurons against excitotoxicity:
bioenergetic effects of mild mitochondrial uncoupling and caloric
restriction. Ann NY Acad Sci. 1147:275–282. 2008.
|
